Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

U.S. Insurers Often Limit Biosimilar Coverage

Lisa Rapaport  |  May 29, 2020

(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsHealth Insuranceinfliximab-abdainfliximab-dyybpharmacy benefit managers (PBMs)

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions

Catherine Kolonko  |  May 18, 2020

At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicscoronavirusCOVID-19cytokine storm syndromeCytokinesmacrophage activation syndrome

Jennifer Elliott, MD

The Nebraska Rheumatology Society Grows to Meet State’s Challenges

Linda Childers  |  May 15, 2020

As state rheumatology societies go, the Nebraska Rheuma­tology Society (NRS) is one of the new kids on the block. Established two years ago, the NRS hopes to involve all 27 rheumatologists across the state. Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center (UNMC), Omaha, says the state’s rheumatologists are spread across…

Filed under:Legislation & AdvocacyProfessional TopicsWorkforce Tagged with:accessNebraska Rheumatology Society (NRS)workforce shortage

Sentavio / shutterstock.com

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

Kimberly Retzlaff  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…

Filed under:Biologics/DMARDsConditionsRheumatoid Arthritis Tagged with:costsjanus kinase inhibitorMethotrexateWinter Rheumatology Summit

Yes, the FDA Employs Rheumatologists. Here’s Their Role.

Renée Bacher  |  April 15, 2020

Ever wonder what role physician regulators—rheumatologists, in particular—perform at the U.S. Food & Drug Administration (FDA)? “I am not sure that many practicing rheumatologists know there are clinicians who work for the FDA,” says rheumatologist Nadia Habal, MD, a medical officer in the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA. “It would…

Filed under:Drug Updates Tagged with:U.S. Food and Drug Administration (FDA)

Experts Discuss Current Insurance Issues Challenging Rheumatology

Thomas R. Collins  |  March 12, 2020

ATLANTA—From step therapy requirements to infusion center locations to evaluation and management coding, insurance issues bring frequent headaches to clinicians and patients. Experts discussed some of the most recent concerns in a session at the 2019 ACR/ARP Annual Meeting. Chris Phillips, MD, chair of the ACR’s Insurance Subcommittee (ISC), and Gary Bryant, MD, delegate to…

Filed under:Billing/CodingLegislation & AdvocacyMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingConsultation CodesHealth Insurancestep therapy

Range of Insurance Issues Challenge Rheumatology

Thomas R. Collins  |  February 12, 2020

ACR representatives updated members on recent insurance issues…

Filed under:Uncategorized

Biologic Spending & Price Trends

Arthritis & Rheumatology  |  January 28, 2020

Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiologic drugsDisease-modifying antirheumatic drugs (DMARDs)etanerceptinfliximab

ACR Advocacy: 2019 Year in Review

Blair Solow, MD  |  January 5, 2020

As a new year begins, Government Affairs Committee chair Blair Solow, MD, takes stock of ACR advocacy wins in 2019 and issues to watch in 2020.

Filed under:Legislation & Advocacy Tagged with:Blair SolowGovernment Affairs Committee (GAC)legislation and advocacy

Coding Corner Answers: Rheumatology Word Search

From the College  |  December 18, 2019

Take the challenge. Answers Biosimilars Methotrexate Time Presenting problem Ultrasound guidance International Classification of Diseases Current Procedural Terminology Trigger points Osteoporosis Osteoarthritis

Filed under:Billing/CodingFrom the College Tagged with:Evaluation and Managementinfliximab

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences